fb-pixel Skip to main content

Latest Headlines in Healthcare

An infusion of Aduhelm, Biogen's controversial recently approved drug for early Alzheimer's disease, at Butler Hospital, one of the clinical research sites.

Biogen says pricey new Alzheimer’s drug reflects treatment’s overall value. Critics vehemently disagree

Amid the fierce backlash over the $56,000 annual price tag for its controversial new Alzheimer’s drug, Biogen is emphasizing another rationale beyond the benefits of reducing the staggering toll of the illness: Other novel medicines using similar technology are much more expensive.

John Malone is a cable television executive, former CEO of Tele-Communications Inc., and chairman of Liberty Media, which owns the Atlanta Braves.

Colorado couple donates $25m to Maine Medical Center

The largest single donation to the hospital comes from John and Leslie Malone, who spend summers in Boothbay Harbor. Leslie Malone recently received cardiac care at the hospital.

Hospitals and doctors had raised concerns that the now-postponed UnitedHealthcare policy signaled a return to a contentious tactic used by health insurers to clamp down on care they argued should be delivered in a less costly setting.

Outcry forces UnitedHealthcare to delay plan to deny coverage for some ER visits

Just days after UnitedHealthcare announced that it would stop paying for emergency room hospital visits that it deemed nonurgent, the company faced mounting opposition and said Thursday it would delay the policy shift until the pandemic had ended.

Henry Magendantz, a patient in the Biogen aducanumab trial, after an infusion in Providence.

CEO of CVS says Biogen Alzheimer’s drug won’t break the bank right away

CVS, which operates one of the largest US health-insurance businesses, is evaluating the drug while it awaits word from the Centers for Medicare and Medicaid Services on how the government agency plans to pay for it.

Dr. Rushika Fernandopulle, cofounder and CEO of Iora Health, a Boston-based company that runs primary care clinics across the country.

Boston’s Iora Health acquired by One Medical in $2.1 billion health tech deal

Iora operates nearly 50 primary care centers across nine states, including one in Hyannis, and has about 600 employees.

Dr. William Burke goes over a PET brain scan at Banner Alzheimer's Institute in Phoenix.

What’s next for Biogen’s newly approved Alzheimer’s drug?

Here’s what you need to know about this historic decision and what happens next.

The Food and Drug Administration campus in Silver Spring, Md. The agency announced a landmark decision on Monday, approving Biogen’s Alzheimer’s drug for use in the United States.

Read the FDA’s decision letter on Biogen’s Alzheimer’s drug

The FDA approved Aduhelm using the Accelerated Approval pathway, which allows it to clear drugs that are likely to result in a benefit for patients, but where there still remains some uncertainty.

Kirsten Hano, a 54-year-old former advertising executive, was diagnosed in November with early-onset Alzheimer's disease. She is hoping that the FDA approves Biogen's controversial drug aducanumab, which would be the first new medicine for Alzheimer's in nearly two decades

As FDA decides on Biogen drug for Alzheimer’s, patients and families hold out hope

The FDA is scheduled to announce a decision on aducanumab by Monday in one of its most closely watched rulings in years. The backstory of the drug, intended to delay cognitive decline in the early phase of Alzheimer’s disease, has been marked by soaring hopes and disheartening setbacks.